Interventions to improve outcomes in community-acquired pneumonia

References

• Torres A, Cilloniz C, Niederman MS, et al. Pneumonia. Nat Rev Dis Primers. 2021;7(1):25. doi: 10.1038/s41572-021-00259-0
   PubMed Web of Science ®Google Scholar
• Vos T, Lim SS, Abbafati C, et al. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the global burden of disease study 2019. Lancet. 2020;396(10258):1204–1222. doi: 10.1016/S0140-6736(20)30925-9
   PubMed Web of Science ®Google Scholar
• JustActions. The Missing Piece. Why the global pandemic is an inflection point for pneumonia control. Revised and updated for COVID-19 and the Global Burden of Disease 2019. Stop Pneumonia/Every Breath Counts. 2021 [cited 2022 Oct 31]. Available from: https://stoppneumonia.org/the-missing-piece-why-the-global-pandemic-is-an-inflection-point-for-pneumonia-control/
   Google Scholar
• Ramirez JA, Wiemken TL, Peyrani P, et al. Adults hospitalized with pneumonia in the United States: incidence, epidemiology, and mortality. Clin Infect Dis. 2017;65(11):1806–1812. doi: 10.1093/cid/cix647
   PubMed Web of Science ®Google Scholar
• Cavallazzi R, Furmanek S, Arnold FW, et al. The burden of community-acquired pneumonia requiring admission to ICU in the United States. Chest. 2020;158(3):1008–1016. doi: 10.1016/j.chest.2020.03.051
   PubMedGoogle Scholar
• Cillóniz C, Dominedò C, Pericàs JM, et al. Community-acquired pneumonia in critically ill very old patients: a growing problem. Eur Respir Rev. 2020;29(155):190126. doi: 10.1183/16000617.0126-2019
   PubMed Web of Science ®Google Scholar
• Cilloniz C, Ceccato A, San Jose A, et al. Clinical management of community acquired pneumonia in the elderly patient. Expert Rev Respir Med. 2016;10(11):1211–1220. doi: 10.1080/17476348.2016.1240037
   PubMed Web of Science ®Google Scholar
• Arnold FW, Reyes Vega AM, Salunkhe V, et al. Older adults hospitalized for pneumonia in the United States: incidence, epidemiology, and outcomes. J Am Geriatr Soc. 2020;68(5):1007–1014. doi: 10.1111/jgs.16327
   PubMed Web of Science ®Google Scholar
• Hu Y, Han Y, Yu C, et al. The hospitalization burden of all-cause pneumonia in China: a population-based study, 2009-2017. Lancet Reg Health West Pac. 2022;22:100443. doi: 10.1016/j.lanwpc.2022.100443
   PubMedGoogle Scholar
• Naucler P, Henriques-Normark B, Hedlund J, et al. The changing epidemiology of community-acquired pneumonia: nationwide register-based study in Sweden. J Intern Med. 2019;286(6):689–701. doi: 10.1111/joim.12956
   PubMed Web of Science ®Google Scholar
• Søgaard M, Nielsen RB, Schønheyder HC, et al. Nationwide trends in pneumonia hospitalization rates and mortality, Denmark 1997–2011. Respir med. 2014;108(8):1214–1222. doi: 10.1016/j.rmed.2014.05.004
   PubMed Web of Science ®Google Scholar
• Dela Cruz CS, Feldman C. COVID-19. Semin Respir Crit Care Med. 2023;44(1):001–002. doi: 10.1055/s-0042-1759777
   PubMedGoogle Scholar
• Lawrence H, Lim WS, McKeever TM. Variation in clinical outcomes and process of care measures in community acquired pneumonia: a systematic review. Pneumonia (Nathan). 2020;12(1):10. doi: 10.1186/s41479-020-00073-4
   PubMedGoogle Scholar
• Moberley S, Holden J, Tatham DP, et al. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev. 2013. CD000422. doi: 10.1002/14651858.CD000422.pub3
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). Current cigarette smoking among adults - United States, 2011. MMWR Morb Mortal Wkly Rep. 2012;61(44):889–894.
   PubMedGoogle Scholar
• Luca DL, Kwong JC, Chu A, et al. Impact of pneumococcal vaccination on pneumonia hospitalizations and related costs in Ontario: a population-based ecological study. Clin Infect Dis. 2017;66(4):541–547. doi: 10.1093/cid/cix850
   Web of Science ®Google Scholar
• Johansson N, Kalin M, Tiveljung-Lindell A, et al. Etiology of community-acquired pneumonia: increased microbiological yield with new diagnostic methods. Clin Infect Dis. 2010;50(2):202–209. doi: 10.1086/648678
   PubMed Web of Science ®Google Scholar
• Rozenbaum MH, Pechlivanoglou P, van der Werf TS, et al. The role of streptococcus pneumoniae in community-acquired pneumonia among adults in Europe: a meta-analysis. Eur J Clin Microbiol Infect Dis. 2013;32(3):305–316. doi: 10.1007/s10096-012-1778-4
   PubMed Web of Science ®Google Scholar
• Huijts SM, Pride MW, Vos JMI, et al. Diagnostic accuracy of a serotype-specific antigen test in community-acquired pneumonia. Eur Respir J. 2013;42(5):1283–1290. doi: 10.1183/09031936.00137412
   PubMed Web of Science ®Google Scholar
• Cillóniz C, Ewig S, Polverino E, et al. Microbial aetiology of community-acquired pneumonia and its relation to severity. Thorax. 2011;66(4):340–346. doi: 10.1136/thx.2010.143982
   PubMed Web of Science ®Google Scholar
• Aliberti S, Cilloniz C, Chalmers JD, et al. Multidrug-resistant pathogens in hospitalised patients coming from the community with pneumonia: a European perspective: table 1. Thorax. 2013;68(11):997–999. doi: 10.1136/thoraxjnl-2013-203384
   PubMed Web of Science ®Google Scholar
• Prina E, Ranzani OT, Polverino E, et al. Risk factors associated with potentially antibiotic-resistant pathogens in community-acquired pneumonia. Ann Am Thorac Soc. 2015;12(2):153–160. doi: 10.1513/AnnalsATS.201407-305OC
   PubMed Web of Science ®Google Scholar
• Cilloniz C, Dominedo C, Peroni HJ, et al. Difficult to treat microorganisms in patients aged over 80 years with community-acquired pneumonia: the prevalence of PES pathogens. Eur Respir J. 2020;56(4):2000773. doi: 10.1183/13993003.00773-2020
   PubMed Web of Science ®Google Scholar
• Jain S, Self WH, Wunderink RG, et al. Community-acquired pneumonia requiring hospitalization among U.S. adults N Engl J Med. 2015;373(5):415–427. doi: 10.1056/NEJMoa1500245
   PubMed Web of Science ®Google Scholar
• Karhu J, Ala-Kokko TI, Vuorinen T, et al. Lower respiratory tract virus findings in mechanically ventilated patients with severe community-acquired pneumonia. Clin Infect Dis. 2014;59(1):62–70. doi: 10.1093/cid/ciu237
   PubMed Web of Science ®Google Scholar
• Wu X, Wang Q, Wang M, et al. Incidence of respiratory viral infections detected by PCR and real-time PCR in adult patients with community-acquired pneumonia: a meta-analysis. Respiration. 2015;89(4):343–352. doi: 10.1159/000369561
   PubMed Web of Science ®Google Scholar
• Zhou F, Wang Y, Liu Y, et al. Disease severity and clinical outcomes of community acquired pneumonia caused by non-influenza respiratory viruses in adults: a multicenter prospective registry study from CAP-China network. Eur Respir J. 2019;54(2):1802406. doi: 10.1183/13993003.02406-2018
   PubMed Web of Science ®Google Scholar
• Cillóniz C, Dominedò C, Magdaleno D, et al. Pure viral sepsis secondary to community-acquired pneumonia in adults: risk and prognostic factors. J Infect Dis. 2019;220(7):1166–1171. doi: 10.1093/infdis/jiz257
   PubMed Web of Science ®Google Scholar
• Marin-Corral J, Pascual-Guardia S, Amati F, et al. Aspiration risk factors, microbiology, and empiric antibiotics for patients hospitalized with community-acquired pneumonia. Chest. 2021;159(1):58–72. doi: 10.1016/j.chest.2020.06.079
   PubMed Web of Science ®Google Scholar
• Weinfurt KP, Reeve BB. Patient-reported outcome measures in clinical Research. JAMA. 2022;328(5):472–473. doi: 10.1001/jama.2022.11238
   PubMed Web of Science ®Google Scholar
• Lloyd M, Callander E, Karahalios A, et al. Patient-reported outcome measures in community-acquired pneumonia: a systematic review of application and content validity. BMJ Open Respir Res. 2019;6(1):e000398. doi: 10.1136/bmjresp-2018-000398
   PubMed Web of Science ®Google Scholar
• Pick HJ, Bolton CE, Lim WS, et al. Patient-reported outcome measures in the recovery of adults hospitalised with community-acquired pneumonia: a systematic review. Eur Respir J. 2019;53(3):1802165. doi: 10.1183/13993003.02165-2018
   PubMed Web of Science ®Google Scholar
• Lloyd MA, Tang CY, Callander EJ, et al. Patient-reported outcome measurement in community-acquired pneumonia: feasibility of routine application in an elderly hospitalized population. Pilot Feasibility Stud. 2019;5(1):97. doi: 10.1186/s40814-019-0481-y
   PubMedGoogle Scholar
• Dong N, Eisenberg JD, Dharmarajan K, et al. Relationship between patient-reported hospital experience and 30-day mortality and readmission rates for acute myocardial infarction, heart failure, and pneumonia. J Gen Intern Med. 2019;34(4):526–528. doi: 10.1007/s11606-018-4746-6
   PubMed Web of Science ®Google Scholar
• Mandell LA, Wunderink RG, Anzueto A, et al. Infectious diseases society of America/American thoracic society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44(Suppl 2):S27–72. doi: 10.1086/511159
   PubMed Web of Science ®Google Scholar
• Garcia-Vidal C, Fernández-Sabé N, Carratalà J, et al. Early mortality in patients with community-acquired pneumonia: causes and risk factors. Eur Respir J. 2008;32(3):733–739. doi: 10.1183/09031936.00128107
   PubMed Web of Science ®Google Scholar
• Luna CM, Palma I, Niederman MS, et al. The impact of age and comorbidities on the mortality of patients of different age groups admitted with community-acquired pneumonia. Ann Am Thorac Soc. 2016;13(9):1519–1526. doi: 10.1513/AnnalsATS.201512-848OC
   PubMed Web of Science ®Google Scholar
• Wadhera RK, Joynt Maddox KE, Wasfy JH, et al. Association of the hospital readmissions reduction program with mortality among medicare beneficiaries hospitalized for heart failure, acute myocardial infarction, and pneumonia. JAMA. 2018;320(24):2542–2552. doi: 10.1001/jama.2018.19232
   PubMed Web of Science ®Google Scholar
• Kolditz M, Tesch F, Mocke L, et al. Burden and risk factors of ambulatory or hospitalized CAP: a population based cohort study. Respir med. 2016;121:32–38. doi: 10.1016/j.rmed.2016.10.015
   PubMed Web of Science ®Google Scholar
• Glöckner V, Pletz MW, Rohde G, et al. Early post-discharge mortality in CAP: frequency, risk factors and a prediction tool. Eur J Clin Microbiol Infect Dis. 2022;41(4):621–630. doi: 10.1007/s10096-022-04416-5
   PubMed Web of Science ®Google Scholar
• Eurich DT, Marrie TJ, Minhas-Sandhu JK, et al. Ten-year mortality after community-acquired pneumonia. A prospective cohort. Am J Respir Crit Care Med. 2015;192(5):597–604. doi: 10.1164/rccm.201501-0140OC
   PubMed Web of Science ®Google Scholar
• Johnstone J, Eurich DT, Majumdar SR, et al. Long-term morbidity and mortality after hospitalization with community-acquired pneumonia: a population-based cohort study. Medicine (Baltimore). 2008;87(6):329–334. doi: 10.1097/MD.0b013e318190f444
   PubMed Web of Science ®Google Scholar
• Uranga A, Quintana JM, Aguirre U, et al. Predicting 1-year mortality after hospitalization for community-acquired pneumonia. PLoS One. 2018;13(2):e0192750. doi: 10.1371/journal.pone.0192750
   PubMed Web of Science ®Google Scholar
• Bordon J, Slomka M, Gupta R, et al. Hospitalization due to community-acquired pneumonia in patients with chronic obstructive pulmonary disease: incidence, epidemiology and outcomes. Clin Microbiol Infect. 2020;26(2):220–226. doi: 10.1016/j.cmi.2019.06.025
   PubMed Web of Science ®Google Scholar
• Dupuis C, Sabra A, Patrier J, et al. Burden of pneumococcal pneumonia requiring ICU admission in France: 1-year prognosis, resources use, and costs. Crit Care. 2021;25(1):24. doi: 10.1186/s13054-020-03442-z
   PubMed Web of Science ®Google Scholar
• Sangla F, Legouis D, Marti P-E, et al. One year after ICU admission for severe community-acquired pneumonia of bacterial, viral or unidentified etiology. What are the outcomes? PLoS One. 2020;15(12):e0243762. doi: 10.1371/journal.pone.0243762
   PubMed Web of Science ®Google Scholar
• Violi F, Cangemi R, Falcone M, et al. Cardiovascular complications and short-term mortality risk in community-acquired pneumonia. Clin Infect Dis. 2017;64(11):1486–1493. doi: 10.1093/cid/cix164
   PubMed Web of Science ®Google Scholar
• Cangemi R, Calvieri C, Falcone M, et al. Relation of cardiac complications in the early phase of community-acquired pneumonia to long-term mortality and cardiovascular events. Am J Cardiol. 2015;116(4):647–651. doi: 10.1016/j.amjcard.2015.05.028
   PubMed Web of Science ®Google Scholar
• Aliberti S, Ramirez JA. Cardiac diseases complicating community-acquired pneumonia. Curr Opin Infect Dis. 2014;27(3):295–301. doi: 10.1097/QCO.0000000000000055
   PubMed Web of Science ®Google Scholar
• Corrales-Medina VF, Suh KN, Rose G, et al. Cardiac complications in patients with community-acquired pneumonia: a systematic review and meta-analysis of observational studies. PLOS Med. 2011;8(6):e1001048. doi: 10.1371/journal.pmed.1001048
   PubMed Web of Science ®Google Scholar
• Feldman C. Cardiac complications in community-acquired pneumonia and COVID-19. Afr J Thorac Crit Care Med. 2020;26(2):26. doi: 10.7196/AJTCCM.2020.v26i2.077
   Google Scholar
• Aldás I, Menéndez R, Méndez R, et al. Early and late cardiovascular events in patients hospitalized for community-acquired pneumonia. Archivos de Bronconeumología. 2020;56(9):551–558. doi: 10.1016/j.arbr.2020.07.003
   PubMed Web of Science ®Google Scholar
• Musher DM, Rueda AM, Kaka AS, et al. The association between pneumococcal pneumonia and acute cardiac events. Clin Infect Dis. 2007;45(2):158–165. doi: 10.1086/518849
   PubMed Web of Science ®Google Scholar
• Anderson R, Nel JG, Feldman C. Multifaceted role of pneumolysin in the pathogenesis of myocardial injury in community-acquired pneumonia. Int J Mol Sci. 2018;19(4):1147. doi: 10.3390/ijms19041147
   PubMed Web of Science ®Google Scholar
• Africano HF, Serrano-Mayorga CC, Ramirez-Valbuena PC, et al. Major adverse cardiovascular events during invasive pneumococcal disease are serotype dependent. Clin Infect Dis. 2021;72(11):e711–e719. doi: 10.1093/cid/ciaa1427
   PubMed Web of Science ®Google Scholar
• Musher DM, Abers MS, Corrales-Medina VF, et al. Acute infection and myocardial infarction. N Engl J Med. 2019;380(2):171–176. doi: 10.1056/NEJMra1808137
   PubMed Web of Science ®Google Scholar
• Putot A, Chague F, Manckoundia P, et al. Post-infectious myocardial infarction: new insights for improved screening. J Clin Med. 2019;8(6):827. doi: 10.3390/jcm8060827
   PubMed Web of Science ®Google Scholar
• Restrepo MI, Reyes LF. Pneumonia as a cardiovascular disease. Respirology. 2018;23(3):250–259. doi: 10.1111/resp.13233
   PubMed Web of Science ®Google Scholar
• Egelund GB, Jensen AV, Petersen PT, et al. Do-not-resuscitate orders in patients with community-acquired pneumonia: a retrospective study. BMC Pulm Med. 2020;20(1):201. doi: 10.1186/s12890-020-01236-1
   PubMed Web of Science ®Google Scholar
• Mortensen EM, Kapoor WN, Chang C-C, et al. Assessment of mortality after long-term follow-up of patients with community-acquired pneumonia. Clin Infect Dis. 2003;37(12):1617–1624. doi: 10.1086/379712
   PubMed Web of Science ®Google Scholar
• Krumholz HM, Lin Z, Keenan PS, et al. Relationship between hospital readmission and mortality rates for patients hospitalized with acute myocardial infarction, heart failure, or pneumonia. JAMA. 2013;309(6):587–593. doi: 10.1001/jama.2013.333
   PubMed Web of Science ®Google Scholar
• Schmitt JP, Kirfel A, Schmitz M-T, et al. The impact of drug interactions in patients with community-acquired pneumonia on hospital length of stay. Geriatrics (Basel). 2022;7(1):11. doi: 10.3390/geriatrics7010011
   PubMedGoogle Scholar
• Mundy LM, Leet TL, Darst K, et al. Early mobilization of patients hospitalized with community-acquired pneumonia. Chest. 2003;124(3):883–889. doi: 10.1378/chest.124.3.883
   PubMed Web of Science ®Google Scholar
• Chen H, Hara Y, Horita N, et al. An early screening tool for discharge planning shortened length of hospital stay for elderly patients with community-acquired pneumonia. Clin Interv Aging. 2021;16:443–450. doi: 10.2147/CIA.S296390
   PubMed Web of Science ®Google Scholar
• Melgaard D, Baandrup U, Bøgsted M, et al. Early mobilisation of patients with community-acquired pneumonia reduce length of hospitalisation—a pilot study. J Phys Ther Sci. 2018;30(7):926–932. doi: 10.1589/jpts.30.926
   PubMedGoogle Scholar
• Rice H, Hill K, Fowler R, et al. Reduced step count and clinical frailty in hospitalized adults with community-acquired pneumonia. Respir Care. 2020;65(4):455–463. doi: 10.4187/respcare.06992
   PubMed Web of Science ®Google Scholar
• Athanassa Z, Makris G, Dimopoulos G, et al. Early switch to oral treatment in patients with moderate to severe community-acquired pneumonia: a meta-analysis. Drugs. 2008;68(17):2469–2481. doi: 10.2165/0003495-200868170-00005
   PubMed Web of Science ®Google Scholar
• Lee RWW, Lindstrom ST. Early switch to oral antibiotics and early discharge guidelines in the management of community-acquired pneumonia. Respirology. 2007;12(1):111–116. doi: 10.1111/j.1440-1843.2006.00931.x
   PubMed Web of Science ®Google Scholar
• Ramirez JA, Srinath L, Ahkee S, et al. Early switch from intravenous to oral cephalosporins in the treatment of hospitalized patients with community-acquired pneumonia. Arch Intern Med. 1995;155(12):1273–1276. doi: 10.1001/archinte.1995.00430120050006
   PubMedGoogle Scholar
• Lee JS, Giesler DL, Gellad WF, et al. Antibiotic therapy for adults hospitalized with community-acquired pneumonia: a systematic review. JAMA. 2016;315(6):593–602. doi: 10.1001/jama.2016.0115
   PubMed Web of Science ®Google Scholar
• Oosterheert JJ, Bonten MJM, Schneider MME, et al. Effectiveness of early switch from intravenous to oral antibiotics in severe community acquired pneumonia: multicentre randomised trial. BMJ. 2006;333(7580):1193. doi: 10.1136/bmj.38993.560984.BE
   PubMed Web of Science ®Google Scholar
• Dharmarajan K, Hsieh AF, Lin Z, et al. Diagnoses and timing of 30-day readmissions after hospitalization for heart failure, acute myocardial infarction, or pneumonia. JAMA. 2013;309(4):355–363. doi: 10.1001/jama.2012.216476
   PubMed Web of Science ®Google Scholar
• Chakrabarti B, Lane S, Jenks T, et al. Predictors of 30-day readmission following hospitalisation with community-acquired pneumonia. BMJ Open Respir Res. 2021;8(1):e000883. doi: 10.1136/bmjresp-2021-000883
   PubMed Web of Science ®Google Scholar
• Toledo D, Soldevila N, Torner N, et al. Factors associated with 30-day readmission after hospitalisation for community-acquired pneumonia in older patients: a cross-sectional study in seven Spanish regions. BMJ Open. 2018;8(3):e020243. doi: 10.1136/bmjopen-2017-020243
   PubMed Web of Science ®Google Scholar
• Tang VL, Halm EA, Fine MJ, et al. Predictors of rehospitalization after admission for pneumonia in the veterans affairs healthcare system. J Hosp Med. 2014;9(6):379–383. doi: 10.1002/jhm.2184
   PubMed Web of Science ®Google Scholar
• Prescott HC, Sjoding MW, Iwashyna TJ. Diagnoses of early and late readmissions after hospitalization for pneumonia. A systematic review. Ann Am Thorac Soc. 2014;11(7):1091–1100. doi: 10.1513/AnnalsATS.201404-142OC
   PubMedGoogle Scholar
• Capelastegui A, España Yandiola PP, Quintana JM, et al. Predictors of short-term rehospitalization following discharge of patients hospitalized with community-acquired pneumonia. Chest. 2009;136(4):1079–1085. doi: 10.1378/chest.08-2950
   PubMed Web of Science ®Google Scholar
• van Walraven C, Bennett C, Jennings A, et al. Proportion of hospital readmissions deemed avoidable: a systematic review. CMAJ. 2011;183(7):E391–402. doi: 10.1503/cmaj.101860
   PubMed Web of Science ®Google Scholar
• Boussat B, Cazzorla F, Le Marechal M, et al. Incidence of avoidable 30-day readmissions following hospitalization for community-acquired pneumonia in France. JAMA Netw Open. 2022;5(4):e226574. doi: 10.1001/jamanetworkopen.2022.6574
   PubMed Web of Science ®Google Scholar
• Halm EA, Fine MJ, Marrie TJ, et al. Time to clinical stability in patients hospitalized with community-acquired pneumonia: implications for practice guidelines. JAMA. 1998;279(18):1452–1457. doi: 10.1001/jama.279.18.1452
   PubMed Web of Science ®Google Scholar
• Dinh A, Duran C, Ropers J, et al. Factors associated with treatment failure in moderately severe community-acquired pneumonia: a secondary analysis of a randomized clinical trial. JAMA Netw Open. 2021;4(10):e2129566. doi: 10.1001/jamanetworkopen.2021.29566
   PubMed Web of Science ®Google Scholar
• Aliberti S, Peyrani P, Filardo G, et al. Association between time to clinical stability and outcomes after discharge in hospitalized patients with community-acquired pneumonia. Chest. 2011;140(2):482–488. doi: 10.1378/chest.10-2895
   PubMed Web of Science ®Google Scholar
• Takada K, Matsumoto S, Kojima E, et al. Predictors and impact of time to clinical stability in community-acquired pneumococcal pneumonia. Respir med. 2014;108(5):806–812. doi: 10.1016/j.rmed.2014.02.007
   PubMed Web of Science ®Google Scholar
• Halm EA, Fine MJ, Kapoor WN, et al. Instability on hospital discharge and the risk of adverse outcomes in patients with pneumonia. Arch Intern Med. 2002;162(11):1278–1284. doi: 10.1001/archinte.162.11.1278
   PubMedGoogle Scholar
• Menéndez R, Torres A, Rodríguez de Castro F, et al. Reaching stability in community-acquired pneumonia: the effects of the severity of disease, treatment, and the characteristics of patients. Clin Infect Dis. 2004;39(12):1783–1790. doi: 10.1086/426028
   PubMed Web of Science ®Google Scholar
• Flateau C, Dinia M, Raulet N, et al. Does a 5-day course of antibiotics in elderly patients with community-acquired pneumonia achieve the established criteria of clinical stability? Infect Dis Now. 2021;51(4):377–379. doi: 10.1016/j.medmal.2020.10.015
   PubMedGoogle Scholar
• Garin N, Felix G, Chuard C, et al. Predictors and implications of early clinical stability in patients hospitalized for moderately severe community-acquired pneumonia. PLoS One. 2016;11(6):e0157350. doi: 10.1371/journal.pone.0157350
   PubMed Web of Science ®Google Scholar
• El Solh AA, Aquilina AT, Gunen H, et al. Radiographic resolution of community-acquired bacterial pneumonia in the elderly. J Am Geriatr Soc. 2004;52(2):224–229. doi: 10.1111/j.1532-5415.2004.52059.x
   PubMed Web of Science ®Google Scholar
• Han X, Liu X, Chen L, et al. Disease burden and prognostic factors for clinical failure in elderly community acquired pneumonia patients. BMC Infect Dis. 2020;20(1):668. doi: 10.1186/s12879-020-05362-3
   PubMed Web of Science ®Google Scholar
• Cillóniz C, Torres A, Niederman MS. Management of pneumonia in critically ill patients. BMJ. 2021;375:e065871. doi: 10.1136/bmj-2021-065871
   PubMedGoogle Scholar
• Cao B, Huang Y, She D-Y, et al. Diagnosis and treatment of community-acquired pneumonia in adults: 2016 clinical practice guidelines by the Chinese thoracic society, Chinese medical association. Clin Respir J. 2018;12(4):1320–1360. doi: 10.1111/crj.12674
   PubMed Web of Science ®Google Scholar
• Lim WS, Baudouin SV, George RC, et al. BTS guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax. 2009;64(Suppl 3):iii1–55. doi: 10.1136/thx.2009.121434
   PubMed Web of Science ®Google Scholar
• Valencia M, Badia JR, Cavalcanti M, et al. Pneumonia severity index class v patients with community-acquired pneumonia: characteristics, outcomes, and value of severity scores. Chest. 2007;132(2):515–522. doi: 10.1378/chest.07-0306
   PubMed Web of Science ®Google Scholar
• Ranzani OT, Prina E, Menéndez R, et al. New sepsis definition (sepsis-3) and community-acquired pneumonia mortality. A validation and clinical decision-making study. Am J Respir Crit Care Med. 2017;196(10):1287–1297. doi: 10.1164/rccm.201611-2262OC
   PubMed Web of Science ®Google Scholar
• Charles PGP, Wolfe R, Whitby M, et al. SMART-COP: a tool for predicting the need for intensive respiratory or vasopressor support in community-acquired pneumonia. Clin Infect Dis. 2008;47(3):375–384. doi: 10.1086/589754
   PubMed Web of Science ®Google Scholar
• Postma DF, van Werkhoven CH, van Elden LJR, et al. Antibiotic treatment strategies for community-acquired pneumonia in adults. N Engl J Med. 2015;372(14):1312–1323. doi: 10.1056/NEJMoa1406330
   PubMed Web of Science ®Google Scholar
• Garin N, Genné D, Carballo S, et al. β-lactam monotherapy vs β-lactam–Macrolide combination treatment in moderately severe community-acquired pneumonia. JAMA Intern Med. 2014;174(12):1894–1901. doi: 10.1001/jamainternmed.2014.4887
   PubMed Web of Science ®Google Scholar
• Nie W, Li B, Xiu Q. β-lactam/macrolide dual therapy versus β-lactam monotherapy for the treatment of community-acquired pneumonia in adults: a systematic review and meta-analysis. J Antimicrob Chemother. 2014;69(6):1441–1446. doi: 10.1093/jac/dku033
   PubMed Web of Science ®Google Scholar
• Sligl WI, Asadi L, Eurich DT, et al. Macrolides and mortality in critically ill patients with community-acquired pneumonia: a systematic review and meta-analysis. Crit Care Med. 2014;42(2):420–432. doi: 10.1097/CCM.0b013e3182a66b9b
   PubMed Web of Science ®Google Scholar
• De la Calle C, Ternavasio-de la Vega HG, Morata L, et al. Effectiveness of combination therapy versus monotherapy with a third-generation cephalosporin in bacteraemic pneumococcal pneumonia: a propensity score analysis. J Infect. 2018;76:342–347. doi: 10.1016/j.jinf.2018.01.003
   PubMed Web of Science ®Google Scholar
• Ito A, Ishida T, Tachibana H, et al. Azithromycin combination therapy for community-acquired pneumonia: propensity score analysis. Sci Rep. 2019;9(1):18406. doi: 10.1038/s41598-019-54922-4
   PubMedGoogle Scholar
• Okumura J, Shindo Y, Takahashi K, et al. Mortality in patients with community-onset pneumonia at low risk of drug-resistant pathogens: impact of β-lactam plus macrolide combination therapy. Respirology. 2018;23(5):526–534. doi: 10.1111/resp.13232
   PubMed Web of Science ®Google Scholar
• Phua J, Dean NC, Guo Q, et al. Severe community-acquired pneumonia: timely management measures in the first 24 hours. Crit Care. 2016;20(1):237. doi: 10.1186/s13054-016-1414-2
   PubMedGoogle Scholar
• Ceccato A, Cilloniz C, Martin-Loeches I, et al. Effect of combined β-lactam/Macrolide therapy on mortality according to the microbial etiology and inflammatory status of patients with community-acquired pneumonia. Chest. 2019;155(4):795–804. doi: 10.1016/j.chest.2018.11.006
   PubMed Web of Science ®Google Scholar
• Metlay JP, Waterer GW, Long AC, et al. Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American thoracic society and infectious diseases society of America. Am J Respir Crit Care Med. 2019;200(7):e45–e67. doi: 10.1164/rccm.201908-1581ST
   PubMed Web of Science ®Google Scholar
• Martin-Loeches I, Torres A, Nagavci B, et al. ERS/ESICM/ESCMID/ALAT guidelines for the management of severe community-acquired pneumonia. Intensive care Med. 2023;49(6):615–632. doi: 10.1007/s00134-023-07033-8
   PubMed Web of Science ®Google Scholar
• Webb BJ, Sorensen J, Jephson A, et al. Broad-spectrum antibiotic use and poor outcomes in community-onset pneumonia: a cohort study. Eur Respir J. 2019;54(1):1900057. doi: 10.1183/13993003.00057-2019
   PubMed Web of Science ®Google Scholar
• Cillóniz C, Pericàs JM, Rojas JR, et al. Severe infections due to respiratory viruses. Semin Respir Crit Care Med. 2022;43(1):060–074. doi: 10.1055/s-0041-1740982
   PubMedGoogle Scholar
• Martin-Loeches I, Schultz MJ, Vincent J-L, et al. Increased incidence of co-infection in critically ill patients with influenza. Intensive care Med. 2017;43(1):48–58. doi: 10.1007/s00134-016-4578-y
   PubMed Web of Science ®Google Scholar
• Lee C-C, Chen P-L, Huang Y-T, et al. Prognostic effects of delayed administration of antimicrobial therapy in older persons experiencing bacteremia with or without initial sepsis presentations. J Am Med Dir Assoc. 2022;23(1):73–80. doi: 10.1016/j.jamda.2021.09.021
   PubMed Web of Science ®Google Scholar
• Torres A, Lee N, Cilloniz C, et al. Laboratory diagnosis of pneumonia in the molecular age. Eur Respir J. 2016;48(6):1764–1778. doi: 10.1183/13993003.01144-2016
   PubMed Web of Science ®Google Scholar
• Rhodes A, Evans LE, Alhazzani W, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive care Med. 2017;43(3):304–377. doi: 10.1007/s00134-017-4683-6
   PubMed Web of Science ®Google Scholar
• Uranga A, España PP, Bilbao A, et al. Duration of antibiotic treatment in community-acquired pneumonia: a multicenter randomized clinical trial. JAMA Intern Med. 2016;176(9):1257–1265. doi: 10.1001/jamainternmed.2016.3633
   PubMed Web of Science ®Google Scholar
• Dinh A, Ropers J, Duran C, et al. Discontinuing β-lactam treatment after 3 days for patients with community-acquired pneumonia in non-critical care wards (PTC): a double-blind, randomised, placebo-controlled, non-inferiority trial. Lancet. 2021;397(10280):1195–1203. doi: 10.1016/S0140-6736(21)00313-5
   PubMed Web of Science ®Google Scholar
• Niederman MS, Mandell LA. How low can we go in community-acquired pneumonia therapy? Lancet. 2021;397(10280):1160–1161. doi: 10.1016/S0140-6736(21)00627-9
   PubMed Web of Science ®Google Scholar
• Falcone M, Russo A, Shindo Y, et al. A hypothesis-generating study of the combination of aspirin plus macrolides in patients with severe community-acquired pneumonia. Antimicrob Agents Chemother. 2019;63(2):e01556–18. doi: 10.1128/AAC.01556-18
   PubMed Web of Science ®Google Scholar
• Falcone M, Russo A, Cangemi R, et al. Lower mortality rate in elderly patients with community-onset pneumonia on treatment with aspirin. J Am Heart Assoc. 2015;4(1):e001595. doi: 10.1161/JAHA.114.001595
   PubMed Web of Science ®Google Scholar
• Sexton TR, Zhang G, Macaulay TE, et al. Ticagrelor reduces thromboinflammatory markers in patients with pneumonia. JACC Basic Transl Sci. 2018;3(4):435–449. doi: 10.1016/j.jacbts.2018.05.005
   PubMedGoogle Scholar
• Grudzinska FS, Dosanjh DP, Parekh D, et al. Statin therapy in patients with community-acquired pneumonia. Clin Med. 2017;17(5):403–407. doi: 10.7861/clinmedicine.17-5-403
   PubMed Web of Science ®Google Scholar
• Chung S-D, Tsai M-C, Lin H-C, et al. Statin use and clinical outcomes among pneumonia patients. Clin Microbiol Infect. 2014;20(9):879–885. doi: 10.1111/1469-0691.12544
   PubMed Web of Science ®Google Scholar
• Chalmers JD, Singanayagam A, Murray MP, et al. Prior statin use is associated with improved outcomes in community-acquired pneumonia. Am j med. 2008;121(11):1002–1007.e1. doi: 10.1016/j.amjmed.2008.06.030
   PubMed Web of Science ®Google Scholar
• Havers F, Bramley AM, Finelli L, et al. Statin use and hospital length of stay among adults hospitalized with community-acquired pneumonia. Clin Infect Dis. 2016;62(12):1471–1478. doi: 10.1093/cid/ciw174
   PubMed Web of Science ®Google Scholar
• Sapey E, Patel JM, Greenwood H, et al. Simvastatin improves neutrophil function and clinical outcomes in pneumonia. A pilot randomized controlled clinical trial. Am J Respir Crit Care Med. 2019;200(10):1282–1293. doi: 10.1164/rccm.201812-2328OC
   PubMed Web of Science ®Google Scholar
• Wu A, Good C, Downs JR, et al. The association of cardioprotective medications with pneumonia-related outcomes. PLoS One. 2014;9(1):e85797. doi: 10.1371/journal.pone.0085797
   PubMed Web of Science ®Google Scholar
• Cangemi R, Falcone M, Taliani G, et al. Corticosteroid use and incident myocardial infarction in adults hospitalized for community-acquired pneumonia. Ann Am Thorac Soc. 2019;16(1):91–98. doi: 10.1513/AnnalsATS.201806-419OC
   PubMed Web of Science ®Google Scholar
• Glass F, Lippton H, Kadowitz PJ. Effects of methylprednisolone and hydrocortisone on aggregation of rabbit platelets induced by arachidonic acid and other aggregating substances. Thromb Haemost. 1981;46(4):676–679. doi: 10.1055/s-0038-1653450
   PubMed Web of Science ®Google Scholar
• Cangemi R, Carnevale R, Nocella C, et al. Glucocorticoids impair platelet thromboxane biosynthesis in community-acquired pneumonia. Pharmacol Res. 2018;131:66–74. doi: 10.1016/j.phrs.2018.03.014
   PubMed Web of Science ®Google Scholar
• Bi J, Yang J, Wang Y, et al. Efficacy and safety of adjunctive corticosteroids therapy for severe community-acquired pneumonia in adults: an updated systematic review and meta-analysis. PLoS One. 2016;11(11):e0165942. doi: 10.1371/journal.pone.0165942
   PubMed Web of Science ®Google Scholar
• Siemieniuk RAC, Meade MO, Alonso-Coello P, et al. Corticosteroid therapy for patients hospitalized with community-acquired pneumonia: a systematic review and meta-analysis. Ann Intern Med. 2015;163(7):519–528. doi: 10.7326/M15-0715
   PubMed Web of Science ®Google Scholar
• Tang Q, Chen Q, Li Y, et al. Association between glucocorticoids and mortality in patients with severe pneumonia: a systematic review and meta-analysis based on randomized controlled trials. Comput Math Methods Med. 2022;2022:1–10. doi: 10.1155/2022/1191205
   Web of Science ®Google Scholar
• Stern A, Skalsky K, Avni T, et al. Corticosteroids for pneumonia. Cochrane Database Syst Rev. 2017;12(12): CD007720. doi: 10.1002/14651858.CD007720.pub3
   PubMedGoogle Scholar
• Wu J-Y, Tsai Y-W, Hsu W-H, et al. Efficacy and safety of adjunctive corticosteroids in the treatment of severe community-acquired pneumonia: a systematic review and meta-analysis of randomized controlled trials. Crit Care. 2023;27(1):274. doi: 10.1186/s13054-023-04561-z
   PubMed Web of Science ®Google Scholar
• Saleem N, Kulkarni A, Snow TAC, et al. Effect of corticosteroids on mortality and clinical cure in community-acquired pneumonia: a systematic review, meta-analysis, and meta-regression of randomized control trials. Chest. 2023;163(3):484–497. doi: 10.1016/j.chest.2022.08.2229
   PubMed Web of Science ®Google Scholar
• Shafiq M, Mansoor MS, Khan AA, et al. Adjuvant steroid therapy in community-acquired pneumonia: a systematic review and meta-analysis. J Hosp Med. 2013;8(2):68–75. doi: 10.1002/jhm.1992
   PubMed Web of Science ®Google Scholar
• Meduri GU, Shih M-C, Bridges L, et al. Low-dose methylprednisolone treatment in critically ill patients with severe community-acquired pneumonia. Intensive care Med. 2022;48(8):1009–1023. doi: 10.1007/s00134-022-06684-3
   PubMed Web of Science ®Google Scholar
• Dequin P-F, Meziani F, Quenot J-P, et al. Hydrocortisone in severe community-acquired pneumonia. N Engl J Med. 2023;388(21):1931–1941. doi: 10.1056/NEJMoa2215145
   PubMed Web of Science ®Google Scholar
• Frat J-P, Thille AW, Mercat A, et al. High-flow oxygen through nasal cannula in acute hypoxemic respiratory failure. N Engl J Med. 2015;372(23):2185–2196. doi: 10.1056/NEJMoa1503326
   PubMed Web of Science ®Google Scholar
• Leeies M, Flynn E, Turgeon AF, et al. High-flow oxygen via nasal cannulae in patients with acute hypoxemic respiratory failure: a systematic review and meta-analysis. Syst Rev. 2017;6(1):202. doi: 10.1186/s13643-017-0593-5
   PubMedGoogle Scholar
• Lewis SR, Baker PE, Parker R, et al. High-flow nasal cannulae for respiratory support in adult intensive care patients. Cochrane Database Syst Rev. 2021;3(3): CD010172. doi: 10.1002/14651858.CD010172.pub3
   Google Scholar
• Cutuli SL, Grieco DL, Menga LS, et al. Noninvasive ventilation and high-flow oxygen therapy for severe community-acquired pneumonia. Curr Opin Infect Dis. 2021;34(2):142–150. doi: 10.1097/QCO.0000000000000715
   PubMed Web of Science ®Google Scholar
• Cilloniz C, Pericàs JM, Rojas J. Ceftaroline in severe community-acquired pneumonia. Rev Esp Quimioter. 2022;35(Suppl 1):28–30. doi: 10.37201/req/s01.06.2022
   PubMedGoogle Scholar
• Cillóniz C, Dominedò C, Garcia-Vidal C, et al. Ceftobiprole for the treatment of pneumonia. Rev Esp Quimioter. 2019;32 (Suppl 3):17–23.
   PubMed Web of Science ®Google Scholar
• Kollef MH, Betthauser KD. New antibiotics for community-acquired pneumonia. Curr Opin Infect Dis. 2019;32(2):169–175. doi: 10.1097/QCO.0000000000000526
   PubMed Web of Science ®Google Scholar
• Zhanel GG, Hartel E, Adam H, et al. Solithromycin: a novel fluoroketolide for the treatment of community-acquired bacterial pneumonia. Drugs. 2016;76(18):1737–1757. doi: 10.1007/s40265-016-0667-z
   PubMed Web of Science ®Google Scholar
• Gadsby NJ, Russell CD, McHugh MP, et al. Comprehensive molecular testing for respiratory pathogens in community-acquired pneumonia. Clin Infect Dis. 2016;62(7):817–823. doi: 10.1093/cid/civ1214
   PubMed Web of Science ®Google Scholar
• Aliberti S, Di Pasquale M, Zanaboni AM, et al. Stratifying risk factors for multidrug-resistant pathogens in hospitalized patients coming from the community with pneumonia. Clin Infect Dis. 2012;54(4):470–478. doi: 10.1093/cid/cir840
   PubMed Web of Science ®Google Scholar
• Shorr AF, Zilberberg MD, Reichley R, et al. Validation of a clinical score for assessing the risk of resistant pathogens in patients with pneumonia presenting to the emergency department. Clin Infect Dis. 2012;54(2):193–198. doi: 10.1093/cid/cir813
   PubMed Web of Science ®Google Scholar
• Webb BJ, Dascomb K, Stenehjem E, et al. Derivation and multicenter validation of the drug resistance in pneumonia clinical prediction score. Antimicrob Agents Chemother. 2016;60(5):2652–2663. doi: 10.1128/AAC.03071-15
   PubMed Web of Science ®Google Scholar
• Lui G, HKW T, Lee N, et al. Adherence to treatment guideline improves patient outcomes in a prospective cohort of adults hospitalized for community-acquired pneumonia. Open Forum Infect Dis. 2020;7(5):ofaa146. doi: 10.1093/ofid/ofaa146
   PubMed Web of Science ®Google Scholar
• Dambrava PG, Torres A, Vallès X, et al. Adherence to guidelines’ empirical antibiotic recommendations and community-acquired pneumonia outcome. Eur Respir J. 2008;32(4):892–901. doi: 10.1183/09031936.00163407
   PubMed Web of Science ®Google Scholar
• Kang SH, Jo YH, Lee JH, et al. Antibiotic prescription consistent with guidelines in emergency department is associated with 30-day survival in severe community-acquired pneumonia. BMC Emerg Med. 2021;21(1):108. doi: 10.1186/s12873-021-00505-4
   PubMed Web of Science ®Google Scholar
• Eticha EM, Gemechu WD. Adherence to guidelines for assessment and empiric antibiotics recommendations for community-acquired pneumonia at Ambo University referral hospital: prospective observational study. Patient Prefer Adherence. 2021;15:467–473. doi: 10.2147/PPA.S295118
   PubMed Web of Science ®Google Scholar
• Arnold FW, LaJoie AS, Brock GN, et al. Improving outcomes in elderly patients with community-acquired pneumonia by adhering to national guidelines: community-acquired pneumonia organization international cohort study results. Arch Intern Med. 2009;169(16):1515–1524. doi: 10.1001/archinternmed.2009.265
   PubMedGoogle Scholar
• Niederman MS, Cilloniz C. Aspiration pneumonia. Rev Esp Quimioter. 2022;35(Suppl 1):73–77. doi: 10.37201/req/s01.17.2022
   PubMedGoogle Scholar
• Mandell LA, Niederman MS, Longo DL. Aspiration pneumonia. N Engl J Med. 2019;380(7):651–663. doi: 10.1056/NEJMra1714562
   PubMed Web of Science ®Google Scholar
• Khadka S, Khan S, King A, et al. Poor oral hygiene, oral microorganisms and aspiration pneumonia risk in older people in residential aged care: a systematic review. Age Ageing. 2021;50(1):81–87. doi: 10.1093/ageing/afaa102
   PubMed Web of Science ®Google Scholar
• Dela Cruz CS, Evans SE, Restrepo MI, et al. Understanding the host in the management of pneumonia. An official American thoracic society workshop report. Ann Am Thorac Soc. 2021;18(7):1087–1097. doi: 10.1513/AnnalsATS.202102-209ST
   PubMed Web of Science ®Google Scholar
• Cilloniz C, Ward L, Mogensen ML, et al. Machine-learning model for mortality prediction in patients with community-acquired pneumonia: development and validation study. Chest. 2023;163(1):77–88. doi: 10.1016/j.chest.2022.07.005
   PubMed Web of Science ®Google Scholar
• Chumbita M, Cillóniz C, Puerta-Alcalde P, et al. Can artificial intelligence improve the management of pneumonia. J Clin Med. 2020;9(1):248. doi: 10.3390/jcm9010248
   PubMed Web of Science ®Google Scholar
• Stokes K, Castaldo R, Federici C, et al. The use of artificial intelligence systems in diagnosis of pneumonia via signs and symptoms: a systematic review. Biomed Signal Process Control. 2022;72:103325. doi: 10.1016/j.bspc.2021.103325
   Web of Science ®Google Scholar